All clinical trials on the European Union Clinical Trials Register (EUCTR) must report their results in the registry within a year of completion. This site tracks who's doing this and who isn't. Learn more »
These trials completed more than 12 months ago and should have reported results. Some have, some have not.
These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.
These trials have problematic data on the registry. Details why »
Status | Trial ID | Title | Completion date | Category |
---|---|---|---|---|
Ongoing | 2007-004539-44 | SEQUENTIAL TREATMENT STRATEGY FOR METASTATIC COLORECTAL CANCER: A PHASE III PROSPECTIVE RANDOMIZED MULTICENTER STUDY OF CHEMOTHERAPY (CT) WITH OR WITHOUT BEVACIZUMAB AS FIRST-LINE THERAPY FOLLOWED BY ... | not-yet-due | |
Ongoing | 2007-005517-20 | Receptor radionuclide therapy with [177Lu- DOTA]0,Tyr3-octreotate (177Lu-DOTATATE): a phase II trial. | not-yet-due | |
Completed, but no date Terminated | 2008-002838-30 | Phase II, randomized, multicentric study of docetaxel and zoledronic acid versus zoledronic acid in patient with prostate cancer and bone metastase treated with LHRH | bad-data | |
Completed, but no date Terminated | 2008-006366-29 | IMMUNOTHERAPY OF MAINTENANCE IN THE PATIENTS WITH METASTATIC MELANOMA, CLINICAL BENEFIT AFTER CHEMOTHERAPY | bad-data | |
Ongoing | 2008-006525-14 | CISPLATIN AND DOCETAXEL FOLLOWED BY SHORT-COURSE OF RADIOTHERAPY AND CONSOLIDATION CHEMOTHERAPY WITH CIPLATIN AND DOCETAXEL IN INOPERABLE NON SMALL CELL LUNG CANCER (NSCLC-STAGE III). | not-yet-due | |
Ongoing | 2009-014662-26 | Phase II comparative study of Myocet plus Cyclophosphamide plus metformin versus Myocet plus Cyclophosphamide in first line treatment of HER2 negative metastatic breast cancer patients. | not-yet-due | |
Ongoing | 2010-018333-21 | Receptorial radiotherapy with 177Lu-DOTA-Tyr3-Octreotate as Maintaining Therapy in Extended Small Cell Lung Cancer (SCLC) after a first standard chemotherapy line | not-yet-due | |
Not reported Terminated | 2010-019841-25 | A Phase II Study to evaluate activity and toxicity of Gemcitabine in Combination with Pemetrexed long term infusion in the Treatment of pretreated Metastatic Colorectal Cancer Patients Studio di fa... | 2014-07-15 | due-trials |
Ongoing | 2010-020189-37 | A randomised phase II study of pre-operative or peri-operative docetaxel, oxaliplatin, capecitabine (DOX) regimen in patients with locally advanced resectable gastric cancer STUDIO DI FASE II RANDO... | not-yet-due | |
Ongoing | 2010-020379-22 | Phase II study of hypofractionated radio-chemotherapy with gemcitabine plus oxaliplatin for unresectable nonmetastatic locally advanced pancreatic cancer. | not-yet-due | |
Ongoing | 2010-020772-38 | A Phase II Study of Dose Density Regimen with Fluorouracil, Epirubicin and Cyclophosphamide at Days 1, 4 Every 14 Days with Filgrastim Support followed by Weekly Paclitaxel in Women with Primary Breas... | not-yet-due | |
Ongoing | 2010-021248-16 | ANGIOGENESIS IMAGING WITH CONTRAST-ENHANCED ULTRASOUND (CEUS) IN COLORECTAL CANCER PATIENTS WITH LIVER METASTASES TREATED WITH BEVACIZUMAB | not-yet-due | |
Ongoing | 2011-002891-18 | Receptorial radiotherapy with 177Lu DOTATATE in somatostatine receptors positive tumours, a phase II study. Radioterapia recettoriale con 177Lu-DOTATATE in tumori con recettori positivi per la soma... | not-yet-due | |
Ongoing | 2012-001410-41 | Vaccination with autologous dendritic cells loaded with autologous tumor lysate or homogenate combined with immunomodulating radiotherapy and/or preleukapheresis IFN-alfa in patients with metastatic m... | not-yet-due | |
Ongoing | 2012-001786-32 | Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with High-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic resp... | not-yet-due | |
Completed, but no date Terminated | 2012-003510-13 | A phase II non randomized study evaluating the role of Androgen Receptors as Targets for therapy of pre-treated post-menopausal patients with ER/PgR-negative/AR-positive or ER and/or PgR-positive/AR-p... | bad-data | |
Completed, but no date | 2012-003544-68 | Randomized cross-over study of patient preference for oral or intravenous vinorelbine in the treatment of advanced NSCLC. A phase IV study. Studio randomizzato cross-over per la valutazione della p... | bad-data | |
Completed, but no date Terminated | 2013-003150-25 | Phase II Trial of Temozolomide in Patients affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer with MGMT methylation. GOPAV03 | bad-data | |
Ongoing | 2014-002602-20 | CLINICAL AND TRASLATIONAL PHASE II STUDY OF LIPOSOMAL DOXORUBICIN PLUS DOCETAXEL AND TRASTUZUMAB WITH METFORMIN AS PRIMARY SYSTEMIC THERAPY FOR OPERABLE AND LOCALLY ADVANCED HER2 POSITIVE BREAST CAN... | not-yet-due | |
Not reported Terminated | 2014-003067-38 | 177Lutethium - Peptide Receptor Radionuclide Therapy (Lu-PRRT) plus Capecitabine versus Lu-PRRT in FDG positive, gastro-entero-pancreatic neuroendocrine tumors: a randomized phase II study. (Lu-Ca-S) ... | 2023-04-30 | due-trials |
Completed, but no date Terminated | 2014-003418-10 | PEPTIDE RECEPTOR RADIONUCLIDE THERAPY WITH 90Y-DOTATOC IN RELAPSED/REFRACTORY DIFFUSE LARGE B CELL AND MANTLE CELL LYMPHOMAS | bad-data | |
Ongoing | 2014-005095-28 | Olaparib as salvage treatment for cisplatin-resistant germ cell tumor. Olaparib as salvage treatment for cisplatin-resistant germ cell tumor. | not-yet-due | |
Completed, but no date Terminated | 2014-005123-27 | Complementary vaccination with dendritic cells pulsed with autologous tumor lysate in resected stage III and IV melanoma patients: a phase II randomized trial (ACDC adjuvant Trial) Complementary v... | bad-data | |
Completed, but no date Terminated | 2015-000556-14 | Vaccination with dendritic cells pulsed with autologous tumor homogenate in combination with HD-IL2 and immunomodulating radiotherapy in metastatic RCC: a phase II trial (RENALVax-2) Vaccination wi... | bad-data | |
Other | 2015-000894-11 | Vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV colorectal cancer: a phase II study Vaccinazione complementare con cellule... | not-yet-due | |
Completed, but no date Terminated | 2015-002419-14 | Phase II study of oral PRednisone 5 mg bid plus EVerolimus in patients with metastatic renal cell cancer after failure of vascular endothelial growth factor receptor-tyrosine kinase inhibitors (PREV s... | bad-data | |
Ongoing | 2015-003397-33 | 68Ga-PSMA HBED-PET/CT in the evaluation of the biochemical relapse in patients with a history of prostate cancer radically treated. Utilizzo di 68Ga-PSMA-HBED PET/CT nella valutazione della ripresa... | not-yet-due | |
Ongoing | 2015-004727-31 | RANDOMIZED PHASE II TRIAL IN SSTr2 POSITIVE TUMORS TO OPTIMIZE THE INTERVAL BETWEEN CYCLES OF PRRT WITH 177LU DOTATATE (LUTHREE) Studio di fase II randomizzato finalizzato ad ottimizzare l’interva... | not-yet-due | |
Not reported Terminated | 2016-000767-17 | A randomized phase II trial of captem or folfiri as SEcond-line therapy in NEuroendocrine CArcinomas and exploratory analysis of predictive role of PET imaging and biological markers (SENECA study) ... | 2021-02-11 | due-trials |
Ongoing | 2016-002732-32 | Radiometabolic Therapy (RMT) with 177Lu PSMA 617 in advanced castration resistant prostate cancer (CRPC): efficacy and toxicity evaluation Terapia radiometabolica (RMT) con 177Lu PSMA 617 nei tumor... | not-yet-due | |
Not reported Terminated | 2016-004107-31 | Randomized clinical trial of concomitant chemoendocrine therapy versus chemotherapy followed by endocrine therapy as first line treatment of luminal B metastatic breast cancer. Studio clinico rando... | 2021-12-31 | due-trials |
Ongoing | 2016-004376-21 | Investigation of 68GaPSMA PET/CT as an imaging biomarker in solid tumors BASKET GA-PSMA: ruolo della PET/TC con 68Ga-PSMA nello studio delle patologie oncologiche | not-yet-due | |
Other | 2016-004452-29 | Randomized, multicentre phase II trial of the sequencing of Radium-223 and Docetaxel plus prednisone in symptomatic bone-only metastatic castration-resistant prostate cancer (mCRPC) Studio randomiz... | not-yet-due | |
Ongoing | 2017-002651-28 | Multi-cohort investigational study to evaluate the impact of pelvic mp-3TMRI and whole-body 68Ga-PSMA PET/CT for diagnosis of clinically-significant prostate cancer and pre-surgical staging. Studio... | not-yet-due | |
Other | 2019-000793-27 | A phase II study on adjuvant Vaccination with dendritic cells loaded with autologous tumor homogenate in resected stage IV rare cancers: Head&Neck (H&N), neuroendocrine Tumors (NET) and soft tissue sa... | not-yet-due | |
Not reported | 2019-002000-41 | Experimental study to evaluate the impact of 18F-PSMA PET / CT in the management of patients with prostate cancer. Studio sperimentale per valutare l'impatto della PET / TC 18F-PSMA nella gestione ... | 2023-06-17 | due-trials |
Completed, but no date Terminated | 2020-001501-24 | PROTECT: A randomized study with Hydroxychloroquine versus observational support for prevention or early phase treatment of Coronavirus disease (COVID-19). PROTECT: studio randomizzato con idrossic... | bad-data | |
Other | 2020-003755-15 | Vaccination with Autologous Dendritic cells loaded with Autologous Tumour homogenate in Glioblastoma: a phase II Study Vaccinazione con Cellule Dendritiche Autologhe caricate con omogenato tumorale... | not-yet-due | |
Ongoing | 2020-004834-39 | Phase 2 trial of Translational approach to first line cHemo-immunotherapy followed by maintenance with pembrOlizumab and olaparib in Extensive-Stage Small-Cell Lung CanceR Studio di fase 2 sull'app... | not-yet-due | |
Ongoing | 2022-001939-88 | Phase II study of Gemcitabine plus Nab-Paclitaxel in combination with Losartan followed by Stereotactic Radiotherapy for Locally Advanced Pancreatic Cancer Studio di Fase II di Gemcitabina e Nab-Pa... | not-yet-due | |
Other | 2022-003786-38 | 68Ga-FAPI-46 PET-CT for molecular assessment of fibroblast activation and risk assessment in solid tumors 68Ga-FAPI-46 PET/CT per la valutazione molecolare dell’attivazione dei fibroblasti e valuta... | not-yet-due | |
Ongoing | 2023-000086-14 | Receptor radionuclide therapy with 177Lu-DOTATOC (177Lu-edotreotide or 177Lu-octreotide) in SSTR positive patients: a multicenter, prospective, phase II trial Terapia radionuclidica recettoriale co... | not-yet-due |